Massachusetts Society of Clinical Oncologists - FDA Approval for Expanded Use of ibrutinib (imbruvica)

"The voice for cancer physicians and their patients in Massachusetts."

Home
For Professionals
FDA Approvals
FDA Approval for Expanded Use of ibrutinib (imbruvica)

FDA Approval for Expanded Use of ibrutinib (imbruvica)

05 Feb 2019 1:50 PM | Anonymous

The U.S. Food and Drug Administration approved the expanded use of ibrutinib (imbruvica; Pharmacyclics) in combination with obinutuzumab for adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL). Read full press release.

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org